Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Aarons

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
European Journal of Clinical Pharmacology|January 1, 1994
Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic softwareL Aarons, L P Balant, F Mentré, et al.
European Journal of Clinical Pharmacology|January 1, 1996
Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studiesL Aarons, L P Balant, F Mentre, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 31, 1998
Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to childrenL Aarons, M Rowland, A Khan, et al.
British Journal of Pharmacology|October 21, 2017
Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus doseS Y A Cheung, T Rodgers, L Aarons, et al.
The Journal of Biological Chemistry|September 15, 1987
An antibody that blocks insulin-like growth factor (IGF) binding to the type II IGF receptor is neither an agonist nor an inhibitor of IGF-stimulated biologic responses in L6 myoblastsW Kiess, J F Haskell, L Lee, et al.
Clinical Pharmacology and Therapeutics|December 1, 1999
Population pharmacokinetics of mefloquine in patients with acute falciparum malariaJ A Simpson, R Price, F ter Kuile, et al.
The Journal of Rheumatology|February 7, 1998
Ascorbic acid absorption in patients with systemic sclerosisL S Teh, C W Johns, J L Shaffer, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 23, 2017
Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade GliomasY T Patel, V M Daryani, P Patel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2011
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1S J Danson, P Johnson, T H Ward, et al.
Mathematical Medicine and Biology : a Journal of the IMA|January 14, 2017
Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patientsN Eymard, V Volpert, P Kurbatova, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
European Journal of Clinical Pharmacology|January 1, 1994
Population approaches in drug development. Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic softwareL Aarons, L P Balant, F Mentré, et al.
European Journal of Clinical Pharmacology|January 1, 1996
Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studiesL Aarons, L P Balant, F Mentre, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 31, 1998
Plasma and tonsillar tissue pharmacokinetics of teicoplanin following intramuscular administration to childrenL Aarons, M Rowland, A Khan, et al.
British Journal of Pharmacology|October 21, 2017
Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus doseS Y A Cheung, T Rodgers, L Aarons, et al.
The Journal of Biological Chemistry|September 15, 1987
An antibody that blocks insulin-like growth factor (IGF) binding to the type II IGF receptor is neither an agonist nor an inhibitor of IGF-stimulated biologic responses in L6 myoblastsW Kiess, J F Haskell, L Lee, et al.
Clinical Pharmacology and Therapeutics|December 1, 1999
Population pharmacokinetics of mefloquine in patients with acute falciparum malariaJ A Simpson, R Price, F ter Kuile, et al.
The Journal of Rheumatology|February 7, 1998
Ascorbic acid absorption in patients with systemic sclerosisL S Teh, C W Johns, J L Shaffer, et al.
CPT: Pharmacometrics & Systems Pharmacology|March 23, 2017
Population Pharmacokinetics of Selumetinib and Its Metabolite N-desmethyl-selumetinib in Adult Patients With Advanced Solid Tumors and Children With Low-Grade GliomasY T Patel, V M Daryani, P Patel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 8, 2011
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1S J Danson, P Johnson, T H Ward, et al.
Mathematical Medicine and Biology : a Journal of the IMA|January 14, 2017
Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patientsN Eymard, V Volpert, P Kurbatova, et al.
Pageof 11